KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non-Current Liabilities (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Other Non-Current Liabilities for 18 consecutive years, with $2.1 billion as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Liabilities rose 26.98% year-over-year to $2.1 billion; the TTM value through Mar 2026 reached $2.1 billion, up 26.98%, while the annual FY2025 figure was $2.0 billion, 28.47% up from the prior year.
  • Other Non-Current Liabilities hit $2.1 billion in Q1 2026 for Regeneron Pharmaceuticals, up from $2.0 billion in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $2.1 billion in Q1 2026 and bottomed at $43.7 million in Q3 2023.
  • Average Other Non-Current Liabilities over 5 years is $1.2 billion, with a median of $908.5 million recorded in 2024.
  • Year-over-year, Other Non-Current Liabilities tumbled 92.7% in 2023 and then surged 3432.27% in 2024.
  • Regeneron Pharmaceuticals' Other Non-Current Liabilities stood at $638.0 million in 2022, then surged by 33.87% to $854.1 million in 2023, then surged by 83.98% to $1.6 billion in 2024, then increased by 28.47% to $2.0 billion in 2025, then increased by 5.32% to $2.1 billion in 2026.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $2.1 billion, $2.0 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.